(Reuters) -French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to ...

Sanofi plans to make insulin more affordable and accessible for all patients next year. The company has taken action to fix insulin prices at $35 ...

The company's leadership has backed this assertion with a $130 million investment in this new space to attract employees and ...

The U.S. Food and Drug Administration is delaying by three months its decision on whether or not to approve tolebrutinib for ...

Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1Designation earned for one-time ...

Merck, Eli Lilly and AstraZeneca have similarly suspended or outright canceled investments in the U.K. in the past week after ...

Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under ...

Sanofi (NASDAQ:SNY) is one of the Ridiculously Cheap Stocks to Buy According to Analysts. On September 22, Bank of America ...

The French pharma’s venture arm will use the funds to back companies working in immunology, neurology, rare diseases and vaccines.

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...

A Paris court on Wednesday ordered Sanofi and its Winthrop unit to pay 150.7 million euros ($177.1 million) in damages to ...

(Reuters) -French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to ...